Lenalidomide-Epoetin Alfa Versus Lenalidomide Monotherapy in Myelodysplastic Syndromes Refractory to Recombinant Erythropoietin

9 febbraio 2021 Senza categoria
Lenalidomide-Epoetin Alfa Versus Lenalidomide Monotherapy in Myelodysplastic Syndromes Refractory to Recombinant Erythropoietin
0 out of 5 based on 0 user ratings

Journal of Clinical Oncology, Ahead of Print.

Related Posts

Lascia un commento